🕐15.09.09 - 08:27 Uhr

BioPharmica Limited [ASX: BPH] - New IPO Intended for BPH and Investment Overview



Fortbridge Media Release
MEDIA DISTRIBUTION BY



BioPharmica Limited [ASX: BPH] - New IPO Intended for BPH and Investment Overview

BioPharmica Limited (ASX: BPH) is an Australian Securities Exchange listed Company working with Universities, Medical Institutes and Hospitals.

Molecular Discovery Systems (MDSystems) is a 100% owned subsidiary of BioPharmica.

The main focus of the company since its launch in 2006 is drug discovery and the validation of biomarkers for disease, therapy and diagnostics.



BioPharmica intends to seek an IPO for Molecular Discovery Systems on the Australian Securities Exchange.

Under a planned �spin off� process, BioPharmica (ASX Code: BPH) shareholders would receive a share at no cost in Molecular Discovery Systems for every listed BioPharmica share that they hold five days after the date of shareholder approval of the spin off which is anticipated to be on 12th November 2009.



This means that an eligible BioPharmica shareholder could retain the shares they hold in BioPharmica whilst receiving the same number of shares (at no cost) in the new IPO of MDSystems.

The spin off and listing is subject to approval from shareholders and regulatory bodies.

MDSystems has core expertise in high content and high throughput imaging and analysis, providing services for researchers worldwide using their InCell Analyser 1000 which is located at the Western Australian Institute for Medical Research (WAIMR) at Sir Charles Gardiner Hospital in Perth.

The spin off will focus on a possible new anti-cancer therapeutic and a new anti-cancer strategy.

The most recent development in the novel anti-mitotic cancer therapeutic area addresses a market which is one of the primary objectives of current oncology drug discovery today.

Clinically approved anti-mitotic drugs (e.g.

Taxol� and Velban�) currently attract in excess of one billion US dollars in revenue each year.

Since new and improved anti-mitotic drugs can be expected to have a similar revenue potential, they are actively being sought by most pharmaceutical companies.

Please find attached the latest newsletter with the related releases and media on the recent significant developments.



BioPharmica will continue to identify further investment opportunities whilst continuing to build the value of its current investments.

BioPharmica shares are listed on the ASX with the code BPH.

We look forward to updating our shareholders with project developments in the near future.

If you are not already on our email list and would like to be, please go to the BioPharmica website www.biopharmica.com.au and subscribe for online updates.



For further information, please contact:

David Breeze
Chairman

T: +61 8 9328 8366


Fortbridge.NET is a specialist web-based service for clients ("Issuer") of Fortbridge Consulting Pty Ltd.

For all enquiries related to this announcement or any attachments, please contact the Issuer directly on the contact details provided.

DISCLAIMER: The message and attachment issued with this email may contain "forward-looking statements", which are projections that reflect the Issuer`s reasonable beliefs based on information currently available.

Although they may have been approved by qualified persons to be announced in this manner, such statements are subject to various risks and uncertainties that could cause actual results and future events to differ materially from projections expressed or implied by the Issuer.

Therefore, readers are cautioned that "forward-looking statements" are not guarantees of future performance or achievements.

Readers are also encouraged to take notice of any further disclaimers or compliance statements that may be included at the end of each announcement attached, especially those specific to different stock exchanges and their jurisdictions.

Fortbridge is a Public Relations consultancy.

The shareholders in Fortbridge may also be shareholders either directly or indirectly in the companies Fortbridge represents.

PRIVACY: You have been regarded as a relevant contact through research.

If you believe there is another member of your organization who would make better use of announcements like this, please reply to this e-mail and let us know.

If you simply wish to be excluded from our distribution list with no substitute, reply to this e-mail with the subject "Please Remove Me".

Please consider the environment before printing this document.




Products & Services | Jobs